First Trust NASDAQ Cybersecurity ETF vs Cronos Group Inc — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $95.05, while Cronos Group Inc trades at $2.74 (market cap $1.03B). The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CIBR | CRON | |
|---|---|---|
52-Week High | $94.73 | $3.27 |
52-Week Low | $60.74 | $1.95 |
Market Cap | — | $1.03B |
Sector | — | Health |
Enterprise Value | — | $211.19M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Trailing returns across standard periods
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →